STATEMENT OF NEED

Non–small cell lung cancer (NSCLC) has seen significant advances in targeted therapy and immunotherapy in recent years, with human epidermal growth factor 2 (HER2) emerging as a target. Activating HER2 mutations in advanced NSCLC are a rare but important entity. Broad testing for HER2 mutations should be considered for all patients with NSCLC alongside testing for other actionable driver mutations. HER2-mutant NSCLC is now targetable with trastuzumab deruxtecan in addition to the recent approval of 2 HER2 tyrosine kinase inhibitors (TKIs), and several therapies are currently under development in clinical trials (NCCN, 2026). Oncology nurses play a critical role in care delivery, adverse event management, and patient education as HER2-targeted therapies enter the clinic. A comprehensive nursing understanding of HER2-targeted therapy mechanisms, administration, safety profiles, and patient education strategies is critical to maximizing treatment efficacy and improving patient outcomes (Sun et al, 2025). This Satellite Symposium at the 51st Annual Oncology Nursing Society (ONS) Congress, held on May 14, 2026, at 6:00 pm CT, will explore practical nursing strategies in HER2-mutant NSCLC. It will feature perspectives from Zofia Piotrowska, MD, MHS, Associate Professor of Medicine at Harvard Medical School and Clinical Co-Director of the MGB Thoracic Medical Oncology Program at Massachusetts General Hospital; Victoria Sherry, DNP, ANP-BC, AOCNP®, Oncology Nurse Practitioner for Thoracic Malignancies at Penn Medicine Abramson Cancer Center and Advanced Senior Lecturer at the University of Pennsylvania School of Nursing; and Soo-Ryum (Stewart) Yang, MD, Assistant Attending Pathologist and Co-Director of Clinical Biomarker Development in the Early Drug Development Service (Solid Tumor) at Memorial Sloan Kettering Cancer Center. 

TARGET AUDIENCE

Oncology nurses, oncology nurse practitioners, and other healthcare providers involved in the management of patients with non–small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Explain the biologic role of HER2 in NSCLC and the distinctions among HER2 mutation, amplification, and overexpression
• Differentiate HER2-targeted treatment classes by mechanism, administration, and toxicity profile to anticipate nursing priorities in care delivery in patients with NSCLC
• Implement evidence-based care plans that incorporate shared decision making and adverse event monitoring for patients with HER2-mutant NSCLC
• Outline interprofessional, practical interventions that optimize patient care and adherence in NSCLC
  
  

 REGISTRATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development 

A maximum of 1.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for TBD contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.5 ANCC contact hours. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, TCTCN®, ROCN®, and BMTCN® renewal candidates may apply 1.5 ILNA points toward:

• Oncology Nursing Practice (OCN®, CPHON®, AOCNP®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

Zofia Piotrowska, MD, MHS, discloses that she has served on an advisory board/panel or as a consultant for AbbVie, AstraZeneca, Bayer, Black Diamond, BlossomHill, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Genentech, Genmab, Gilead, Janssen, Natera, Nuvalent, Regeneron, Revolution Medicines, Summit, Taiho, Takeda, and Tubulis; and that she has received grants/research support from AbbVie, AstraZeneca, BlossomHill, Blueprint, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, SystImmune, Takeda, and Tesaro/GSK.

Victoria Sherry, DNP, ANP-BC, AOCNP®, has no relevant financial relationships to disclose

Soo-Ryum (Stewart) Yang, MD, discloses that he has served as a consultant for AbbVie, Amgen, AstraZeneca, Eli Lilly, Merus, Revolution Medicines, Roche, and Sanofi.

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL NCPD ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) NCPD activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.